Physicians' Academy for Cardiovascular Education

Benefits and evolving insights on SGLT2i in the spectrum of LVEF

Listen to the podcast
10' education - June 29, 2022 - Prof. Carolyn Lam, MD, PhD - Singapore

Video navigation menu

  • SGLT2i in HFrEF 01:06
  • SGLT2i in HF with LVEF>40% 02:29
  • Current guideline treatment recommendations 05:39
  • SGLT2i in acute HF 08:07
  • Effects of SGLT2i on biomarkes, symptoms and functional status in HFpEF 08:31
  • Concluding remarks 09:31


Show transcript

Educational information

This lecture by prof. Lam was part of the EBAC-accredited symposium "When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options" held during the ESC Heart Failure 2022 congress.


Carolyn Lam is professor at the Duke-NUS Gratuate Medical School in Singapore. She is also a Senior Consultant Cardiologist and Director of Women's Heart Health at the National Heart Centre Singapore, and Rosalind Franklin Fellow at the University Medical Center Groningen in the Netherlands.


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.


Funding for this educational program was provided by an unrestricted educational grant from AstraZeneca.

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: